Novo Seeds leads a €7 million seed investment in Bactolife™, a Danish start-up focused on developing innovative biological solutions to combat gastrointestinal infections while reducing antibiotic use.

Information on the Target

Bactolife™, a Danish start-up founded in 2017, specializes in the development of innovative biological solutions aimed at reducing the risk of gastrointestinal infections in both animals and humans. The company has established a proprietary platform that utilizes nanobody technology to manage bacterial virulence without relying on antibiotics. This technology focuses on selecting and producing Virulence Inactivating Proteins (VIPs™), which effectively inhibit bacterial virulence without fostering antibiotic resistance, making them stable, cost-effective, and scalable through advanced biomanufacturing processes.

The lead product of Bactolife, known as Ablacto+, has demonstrated effectiveness in preventing post-weaning diarrhea (PWD) in piglets, which is caused by E. coli infections. PWD poses significant risks after the weaning phase due to the absence of protective antibodies typically found in sow's milk, crippling piglet health and leading to considerable economic losses in the pig production industry.

Industry Overview in Denmark

The animal farming industry in Denmark plays a pivotal role in the country's economy, contributing significantly to agricultural productivity. However, this industry faces substantial challenges related to the management of animal health and